Dunn HP, et al. - Via retrospective case review of neonates with persistent pulmonary hypertension of the newborn who received sildenafil therapy between 2010 and 2015 in a single, tertiary surgical neonatal intensive care unit in Australia, experts intend to discover the risk of ocular complications of sildenafil therapy in neonates. A total of 27 neonates with persistent pulmonary hypertension of the newborn received sildenafil. They undertook an ophthalmic review in 23 neonates, and 16 neonates were term or near-term infants. It was found that in term or near-term neonates, there were no short-term complications attributable to sildenafil therapy was recognized. In an institution, this cohort of neonates does not typically undergo an ophthalmic examination as part of the retinopathy of prematurity (ROP) screening protocol. Routine ophthalmic review of neonates on sildenafil therapy, who were not at risk of ROP, was hence unlikely to be warranted.